These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38524633)

  • 1. Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA.
    Chen C; Lv J; Liu C
    Front Endocrinol (Lausanne); 2024; 15():1335531. PubMed ID: 38524633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
    Butler J; Zheng Y; Khan MS; Bonderman D; Lund LH; deFilippi CR; Blaustein RO; Ezekowitz JA; Freitas C; Hernandez AF; O'Connor CM; Voors AA; Westerhout CM; Lam CSP; Armstrong PW;
    JACC Heart Fail; 2023 May; 11(5):583-592. PubMed ID: 37137660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
    Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
    J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
    Lam CSP; Giczewska A; Sliwa K; Edelmann F; Refsgaard J; Bocchi E; Ezekowitz JA; Hernandez AF; O'Connor CM; Roessig L; Patel MJ; Pieske B; Anstrom KJ; Armstrong PW;
    JAMA Cardiol; 2021 Jun; 6(6):706-712. PubMed ID: 33185650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
    Pieske B; Pieske-Kraigher E; Lam CSP; Melenovský V; Sliwa K; Lopatin Y; Arango JL; Bahit MC; O'Connor CM; Patel MJ; Roessig L; Morris DA; Kropf M; Westerhout CM; Zheng Y; Armstrong PW;
    Eur J Heart Fail; 2023 Jul; 25(7):1012-1021. PubMed ID: 36994634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and Design of the VITALITY-HFpEF Trial.
    Butler J; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; Wu Y; Carvalho F; Bamber L; Blaustein RO; Roessig L; Armstrong PW
    Circ Heart Fail; 2019 May; 12(5):e005998. PubMed ID: 31096775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
    N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
    Mentz RJ; Stebbins A; Butler J; Chiang CE; Ezekowitz JA; Hernandez AF; Hilkert R; Lam CSP; McDonald K; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Sweitzer NK; Voors AA; Anstrom KJ; Armstrong PW;
    JACC Heart Fail; 2024 May; 12(5):839-846. PubMed ID: 38363272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Kang C; Lamb YN
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
    Lam CSP; Mulder H; Lopatin Y; Vazquez-Tanus JB; Siu D; Ezekowitz J; Pieske B; O'Connor CM; Roessig L; Patel MJ; Anstrom KJ; Hernandez AF; Armstrong PW;
    J Am Heart Assoc; 2021 Nov; 10(22):e021094. PubMed ID: 34743540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging concepts in heart failure management and treatment: focus on vericiguat.
    Kaplinsky E; Perrone S; Barbagelata A
    Drugs Context; 2023; 12():. PubMed ID: 36660012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vericiguat for Heart Failure with Reduced Ejection Fraction.
    Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A
    Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction.
    Oh J; Lee CJ; Park JJ; Lee SE; Kim MS; Cho HJ; Choi JO; Lee HY; Hwang KK; Kim KH; Yoo BS; Choi DJ; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Kang SM
    ESC Heart Fail; 2022 Apr; 9(2):1492-1495. PubMed ID: 35142095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
    Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
    Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vericiguat for the treatment of heart failure with reduced ejection fraction.
    Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.